What This Means
This research suggests that pemafibrate, a drug that activates a protein called PPARα involved in fat metabolism, can treat a common liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD), which involves fat buildup and inflammation in the liver. Using mouse models, cell experiments, and a study of 192 human patients, the researchers found that pemafibrate reduced liver fat accumulation, liver scarring (fibrosis), and the activity of genes that drive inflammation and tissue damage. These benefits appeared to work through two main pathways: reducing levels of the hormone leptin (which at high levels promotes liver inflammation) and improving the balance of bacteria living in the gut.
In fat cell experiments, pemafibrate was shown to directly reduce how much leptin the cells produce by blocking a specific molecular signal triggered by insulin. This translated to lower leptin and insulin levels in the blood and liver of treated mice, which helps explain the reduction in liver inflammation observed. Additionally, pemafibrate changed the gut microbiome in mice by increasing bacteria from the group Verrucomicrobia, which may send beneficial signals to the liver through the gut-liver connection.
In the 192-patient clinical study, patients who received long-term pemafibrate treatment showed meaningful improvements in liver enzyme levels, insulin resistance, markers of liver scarring, and blood leptin levels — findings that closely matched the animal and cell experiments. This research suggests pemafibrate may work on MASLD through multiple complementary mechanisms, and supports further clinical investigation of this drug as a potential disease-modifying treatment for a condition that currently has very limited pharmaceutical options.